Imunon (NASDAQ:IMNN – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.
Volatility and Risk
Imunon has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.3, meaning that its share price is 130% more volatile than the S&P 500.
Insider and Institutional Ownership
4.5% of Imunon shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 5.0% of Imunon shares are held by insiders. Comparatively, 24.1% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Imunon | $500,000.00 | 27.77 | -$19.51 million | ($1.89) | -0.51 |
| Unicycive Therapeutics | $680,000.00 | 92.20 | -$30.54 million | ($0.97) | -0.62 |
Imunon has higher earnings, but lower revenue than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings for Imunon and Unicycive Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Imunon | 0 | 0 | 2 | 1 | 3.33 |
| Unicycive Therapeutics | 0 | 0 | 4 | 1 | 3.20 |
Imunon presently has a consensus target price of $20.50, indicating a potential upside of 2,040.55%. Unicycive Therapeutics has a consensus target price of $5.50, indicating a potential upside of 810.60%. Given Imunon’s stronger consensus rating and higher possible upside, analysts plainly believe Imunon is more favorable than Unicycive Therapeutics.
Profitability
This table compares Imunon and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Imunon | N/A | -230.05% | -128.98% |
| Unicycive Therapeutics | N/A | N/A | -29.88% |
Summary
Unicycive Therapeutics beats Imunon on 9 of the 13 factors compared between the two stocks.
About Imunon
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon’s DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
